Severe acute pancreatitis concurrent with lethal rupture of cerebral aneurysm: A case report and review of the literature

Xu, Yayun; Wang, Jianfa; Zhang, Ziping

doi:10.1016/j.ijscr.2020.08.016

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AP, mainly caused by gallstones, alcohol abuse or hypertriglyceridaemia, is becoming one of the most common emergent GI diseases. Nearly 80% of AP patients exhibit a mild course, and the remaining 20% progress to severe disease, in which systemic inflammatory response syndrome or fatal complications might occur 26,27 . Thanks to the updated 2012 Revised Atlanta Classification for AP diagnosis and grading 13 and multiple Pancreatitis Activity Scoring System for severity prediction, 28 AP patients in the early stage can be identified and undergo initial therapies.…”

Section: Discussionmentioning

confidence: 99%

“…Nearly 80% of AP patients exhibit a mild course, and the remaining 20% progress to severe disease, in which systemic inflammatory response syndrome or fatal complications might occur. 26 , 27 Thanks to the updated 2012 Revised Atlanta Classification for AP diagnosis and grading 13 and multiple Pancreatitis Activity Scoring System for severity prediction, 28 AP patients in the early stage can be identified and undergo initial therapies. Accordingly, the American Gastroenterological Association recommends initial management paradigms in the early stage of AP, such as goal‐directed fluid management.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RORγt inhibitor SR1001 alleviates acute pancreatitis by suppressing pancreatic IL‐17‐producing Th17 and γδ‐T cells in mice with ceruletide‐induced pancreatitis

Wang

Jing

et al. 2021

Basic Clin Pharma Tox

Self Cite

View full text Add to dashboard Cite

The management of acute pancreatitis (AP) remains a challenge to clinicians worldwide for limited effective interventions. Retinoid orphan receptor gamma t (RORγt) is a therapeutic target for several diseases; however, it is unclear whether inhibiting RORγt can ameliorate AP. The relative expression of RORγt, IL‐17 and IL‐23 in the peripheral blood mononuclear cells of AP patients was measured by RT‐PCR. An AP mouse model was induced by ceruletide, and SR1001 was injected before ceruletide administration. RORγt+ cells, T helper 17 cells (Th17), regulatory T cells (Tregs) and γδ T cells were assessed in the pancreas and spleen by flow cytometry. Higher RORγt expression in patients indicated the potential role of RORγt in AP progression. Analyses of the IL‐17/IL‐23 axis confirmed its role. SR1001 significantly alleviated AP histologically in the mouse model. Serum levels of amylase, IL‐6, TNFalpha, IL‐17 and IL‐23 decreased upon SR1001 treatment. SR1001 selectively decreased the number of RORγt+, Th17, Tregs and γδ T cells in the pancreas but not the spleen. Collectively, these results showed that SR1001 exerted therapeutic effects on AP by suppressing IL‐17‐secreting Th17 and γδ T cells in the pancreas. Thus, SR1001 may be a promising drug for the treatment of AP in the clinic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

RORγt inhibitor SR1001 alleviates acute pancreatitis by suppressing pancreatic IL‐17‐producing Th17 and γδ‐T cells in mice with ceruletide‐induced pancreatitis

Wang

Jing

et al. 2021

Basic Clin Pharma Tox

Self Cite

View full text Add to dashboard Cite

show abstract

Prediction and diagnosis of pancreatogenic encephalopathy in patients with destructive pancreatitis

Бебуришвили¹,

Burchuladze²,

Mikhin³

et al. 2022

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

Impact of Demographic Variables on the Risk of Pancreatogenic Encephalopathy in Patients With Nutritional Pancreatonecrosis

Бебуришвили

Mikhin

Burchuladze

et al. 2022

Journal of Volgograd State Medical University

View full text Add to dashboard Cite

Resume. Aim. Study of the dependence of the degree of risk of developing pancreatogenic encephalopathy (PEP) on demographic variables in patients with nutritional pancreatic necrosis. Materials and methods. A single-center prospective cohort non-randomized study was conducted on the basis of the Faculty Surgery Clinic of the Volgograd State Medical University in the period from 2010 to 2020. To determine the significance of the influence of a patient-dependent factor on the risk of developing PEP, ROC analysis was used. Logistic regression analysis was used to determine the degree of risk of developing PEP against the background of a combination of several covariates. Results. The study included 429 patients with pancreatic necrosis of alimentary origin. A comparative analysis of the incidence of PEP was carried out depending on gender and age, the trigger of the disease (alcohol-associated versus non-alcoholic pancreatic necrosis) and comorbid background. It has been proven that significant factors that increase the risk of developing PEP are age over 60 years (p = 0,04), alcohol-associated pancreatic necrosis (p < 0,001) and cardiovascular pathology - ischemic heart disease (p < 0,001). A statistically significant regression model of the effect of cardiovascular pathology on the incidence of PEP has been developed, which makes it possible to calculate the risk of this complication in a particular patient. Conclusions. Significant demographic variables that increase the risk of PEP include age over 60 years, alcoholic pancreatitis, and the presence of coronary artery disease in a patient. The developed logistic model makes it possible to calculate the personalized risk of PEP during hospitalization of a patient with nutritional pancreatic necrosis.

show abstract

Severe acute pancreatitis concurrent with lethal rupture of cerebral aneurysm: A case report and review of the literature

Cited by 4 publications

References 16 publications

RORγt inhibitor SR1001 alleviates acute pancreatitis by suppressing pancreatic IL‐17‐producing Th17 and γδ‐T cells in mice with ceruletide‐induced pancreatitis

RORγt inhibitor SR1001 alleviates acute pancreatitis by suppressing pancreatic IL‐17‐producing Th17 and γδ‐T cells in mice with ceruletide‐induced pancreatitis

Prediction and diagnosis of pancreatogenic encephalopathy in patients with destructive pancreatitis

Impact of Demographic Variables on the Risk of Pancreatogenic Encephalopathy in Patients With Nutritional Pancreatonecrosis

Contact Info

Product

Resources

About